4D Molecular Therapeutics Announces Encouraging Interim Phase 1 Results for 4D-710 in Cystic Fibrosis
Positive Interim Results: 4D Molecular Therapeutics reported encouraging interim results from its Phase 1 AEROW study for 4D-710, a gene therapy for cystic fibrosis, showing significant improvements in lung function over a one-year follow-up.
Durable CFTR Expression: The study demonstrated sustained CFTR transgene expression within the therapeutic range for at least one year, indicating potential long-term benefits for patients.
Future Plans: The company anticipates completing enrollment for the Phase 2 dose-expansion cohort by mid-2026, with an update on the program expected in the latter half of 2026.
Stock Performance: Following the announcement, FDMT shares rose by 5.21%, closing at $11.52.
Get Free Real-Time Notifications for Any Stock
Analyst Views on FDMT
About FDMT
About the author
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees
- Employee Incentive Program: On January 13, 2026, 4D Molecular Therapeutics' compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees, aimed at attracting talent and enhancing team stability.
- Equity Grant Context: The RSUs were awarded under the 2025 Employment Inducement Award Plan, approved by the board in February 2025, complying with Nasdaq Rule 5635(c)(4), reflecting the company's commitment to talent acquisition.
- Product Development Progress: The company's lead product, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods, showcasing transformative potential.
- Gene Therapy Innovation: The second candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, demonstrating the company's innovative capabilities and market potential in the therapeutic landscape.
Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.
